LOTEMAX

This brand name is authorized in United States. It is also authorized in Austria, Canada, Cyprus, Estonia, Hong Kong SAR China, Ireland, Israel, Lithuania, Poland, Singapore, South Africa, Tunisia, Turkey, UK.

Active ingredients

The drug LOTEMAX contains one active pharmaceutical ingredient (API):

1	Loteprednol UNII YEH1EZ96K6 - LOTEPREDNOL ETABONATE
	Loteprednol etabonate is a new class of corticosteroid with potent antiinflammatory activity designed to be active at the site of action. Its antiinflammatory activity is similar to the most powerful steroid used in ophthalmology but with less intraocular pressure.
	Read more about Loteprednol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOTEMAX Eye-drops, suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01BA14	Loteprednol	S Sensory organs → S01 Ophthalmologicals → S01B Antiinflammatory agents → S01BA Corticosteroids, plain
Discover more medicines within S01BA14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02321114, 02421941, 02435853
EE	Ravimiamet	1185184, 1185195, 1185207
GB	Medicines & Healthcare Products Regulatory Agency	134647
HK	Department of Health Drug Office	51822
IL	מִשְׂרַד הַבְּרִיאוּת	6453, 8187
LT	Valstybinė vaistų kontrolės tarnyba	1019880, 1019881, 1019882
PL	Rejestru Produktów Leczniczych	100158382, 100419960
SG	Health Sciences Authority	12601P
TN	Direction de la Pharmacie et du Médicament	24063011
TR	İlaç ve Tıbbi Cihaz Kurumu	8681738340013, 8681738440034, 8699856710038
US	FDA, National Drug Code	24208-299, 24208-443, 24208-503, 24208-507
ZA	Health Products Regulatory Authority	37/15.2/0588